Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paroxetine vs placebo on brain functional activation in major depressive disorder
2007-004025-20Phase 4Terminated
- Sponsor
- GSK
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Paroxetine with Placebo (2 arms). Primary endpoint: Change in brain functional activation in amygdala and anterior cingulate cortex. Started Oct 2007; status: terminated.
02
Drugs
paroxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2007-004025-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004025-20.